PeptidePedia The community reference

Sarcopenia (revision 6)

Old revision·23:12, 10 Jan 2025·CRP_Cormac

This is an old revision of this page, as it stood at 23:12, 10 Jan 2025, saved by CRP_Cormac with the summary expand §Definition and assessment. It may differ substantially from the current revision, and any error it contains may since have been corrected.
Sarcopenia
Defined byLow muscle strength, confirmed by low muscle quantity
Assessed byGrip strength, chair-stand time, gait speed
Not defined byMuscle mass alone
Topic infobox · conventions

Sarcopenia is the loss of skeletal muscle accompanied by loss of strength or physical performance. Current consensus definitions place low muscle strength as the primary criterion, with low muscle quantity as confirmation — a deliberate reversal of earlier mass-based definitions.[1]

The reordering matters for how the topic is discussed in the context of weight reduction. A fall in lean mass measured by body composition assessment is not sarcopenia; a fall in strength or function is the finding that would be.[1]

Concern about sarcopenia during substantial pharmacological weight loss is reasonable in principle, particularly in older people and those with low muscle mass at baseline, and the evidence addressing it directly is limited.[2]

Definition and assessment

[edit]

Consensus definitions require low muscle strength for a probable diagnosis, confirmed by low muscle quantity or quality, with poor physical performance indicating severity.[1]

DomainCommon measures
StrengthGrip strength; chair-stand time
QuantityAppendicular lean mass by DXA
PerformanceGait speed; short physical performance battery

Grip strength is the most widely used screening measure because it is quick, cheap and correlates with strength elsewhere. Its cut-offs are population- and device-specific, as reference intervals generally are.[1]

References

  1. ^ a b c d Cruz-Jentoft AJ, Bahat G, Bauer J, et al. "Sarcopenia: revised European consensus on definition and diagnosis." Age and Ageing 48(1):16–31 (2019). DOI:10.1093/ageing/afy169. PMID 30312372.
  2. ^ Wilding JPH, Batterham RL, Calanna S, et al. "Once-weekly semaglutide in adults with overweight or obesity." New England Journal of Medicine 384(11):989–1002 (2021). PMID 33567185.